Trial Profile
A Phase Ib Clinical Study to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules as First-line Treatment for Advanced Hepatocellular Carcinoma.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2024
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Penpulimab (Primary) ; TQB 2618 (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 07 Aug 2023 New trial record